Nonetheless, the rate of non-BRCA pathogenic variations was higher than those of BRCA1 or BRCA2 pathogenic variations especially in bilateral breast cancer patients (Fanale et al., 2020). This evidence concerns the gene BRCA1 and breast carcinoma.